FIELD : pharmaceutics.SUBSTANCE : invention relates to a novel heterocyclic compound of general formula (I), a pharmaceutically acceptable salt thereof and an enantiomer thereof. In compound of formula (I) Y is selected from -CH2 or -C(O); R1 is selected from following groups (1-1), (1-6), (1-9) and (1-10) : R2, R3, R6 represent a hydrogen atom; R4 is selected from a hydrogen atom or groups selected from above in 1, R5 is selected from halogen, C1-C4 alkyl, C4-C7 cycloalkene or the following groups : with a group Het, representing 1-2 nitrogen atoms in number of 6 aromatic ring atoms and these nitrogen atoms can be independently substituted by an oxygen atom to form an N-oxide group; R7 is selected from the following groupswherein n = 0 or 1; R8, R9, which can be identical or different, are selected from a hydrogen atom, F or -CH3; R10 is selected from a hydrogen atom, -OR11, -SR11, -S(O)R11, -SO2R11, -CO2R11 or halogen; R11, R12, which can be identical or different, are selected from a hydrogen atom, C1-C6 alkyl, CF3 or C1-C6 alkyl ether; R13, R14, R15, which can be identical or different, are selected from a hydrogen atom, C1-C6 alkyl, cycloalkyl, -OR16, halogen, -OCF3, -CF3, -CN, -CO2R16, -CONR16R17, -NO2, -OCH2OR16, -SR16, -S(O)R16 or -SO2R16; A, B, D, which can be identical or different, are selected from C, N or S atom; R16 and R17, which may be identical or different, are selected from a hydrogen atom, C1-C6 alkyl or -C(O)R18; Z is selected from -CH2 or O and R18 is selected from a hydrogen atom, C1-C6 alkyl.EFFECT : compounds have the CGRP-R receptor antagonist properties and can be used in the prevention and/or treatment of inflammatory diseases with a neurogenic component, exempli gratia in the prevention and/or treatment of type I rosacea (erythematous), for the treatment of migraine.10 cl, 4 dwg, 3 tbl, 167 ex